Clinical Trial Update: Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis [Phase 2]

View source ↗

Summary

Phase 2 trial update on 28 days of dosing GSK962040 in adults with gastroparesis; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroparesis

Drugs mentioned

• GSK962040

Snippet

Sponsor: GlaxoSmithKline | Conditions: Gastroparesis | Phase 2 | Status: COMPLETED | Results posted: 2017-10-13